All results
19 results for biomarkers als
-
Testing the Combination of ZEN-3694 and Talazoparib in Ps w/ Advanced Solid Tumors; ComBET
This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely…
- Ages
- 18 Years - N/A
- Sexes
- All
-
EVOLVE
The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid…
- Ages
- 18 Years - 99 Years
- Sexes
- All
-
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Pts w/ MIBC
The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone. Bladder…
- Ages
- 18 Years - N/A
- Sexes
- All
-
ARCH II
This study is being done to learn about the interaction of alcohol consumption and HIV on brain function. The proposed study will have two broad objectives.…
- Ages
- 25 Years - 75 Years
- Sexes
- All
-
Takeda TAK-999-3001
The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down…
- Ages
- 18 Years - 75 Years
- Sexes
- All
-
Study in Parkinson Disease of Exercise (SPARX3)
This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the Movement Disorder Society-Unified…
- Ages
- 40 Years - 80 Years
- Sexes
- All
-
Testing Triapine w/ Targeted Radiation-based LU177 vs Lu177 alone in pts w/ metastatic NETs
This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA)…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Study of XL092 in Comb. with Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002)
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, PK, preliminary antitumor…
- Ages
- 18 Years - N/A
- Sexes
- All